Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
LOS ANGELES, Aug. 25, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (Nasdaq:SVA) for possible violations of federal securities laws from April 30, 2013 through May 16, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired Sinovac shares during the Class Period should contact the firm before the September 1, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet, and until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Sinovac made false and/or misleading statements and/or failed to disclose: that Chairman and CEO Weidong Yin bribed a member of China’s Food and Drug Administration to assist Sinovac’s vaccine clinical trial and approval; that this conduct would subject the Company to heightened regulatory scrutiny; and that as a result of the above, Sinovac’s public statements were materially false and misleading at all relevant times. When this news became public, Sinovac’s stock price decreased materially, which caused investors harm according to the Complaint.
Lundin Law PC was established by Brian Lundin, a securities litigator in Los Angeles dedicated to upholding the rights of shareholders.
This press release may constitute Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
